2021 Fiscal Year Final Research Report

HEG1-responsive microRNA-23b regulates cell proliferation in malignant mesothelioma cells

Research Project

PDF

Project/Area Number	19K07439
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 49020:Human pathology-related
Research Institution	Nara Medical University
Principal Investigator	Itami Hiroe 奈良県立医科大学, 医学部, 講師 (20769020)
Co-Investigator(Kenkyū-buntansha)	中井登紀子国立研究開発法人国立がん研究センター, 東病院, 医員 (00619538) 武田麻衣子奈良県立医科大学, 医学部, 講師 (40398441) 藤井智美奈良県立医科大学, 医学部, 准教授 (50623477) 畠山金太国立研究開発法人国立循環器病研究センター, 病院, 部長 (60325735) 大林千穂奈良県立医科大学, 医学部, 教授 (90223940)
Project Period (FY)	2019-04-01 – 2022-03-31
Keywords	悪性中皮腫 / HEG1 / マイクロRNA
Outline of Final Research Achievements	The molecular target of malignant mesothelioma (MM) has not been elucidated because of unknown survival, death, and cytotoxic signals in MM. HEG homolog 1 (HEG1) is a mucin-like membrane protein that contains epidermal growth factor-like domains, and HEG1 expression supports the survival and proliferation of MM cells. In this study, functional analysis of HEG1 and microRNAs using MM cell lines was performed. MiR-23b contributes to HEG1-dependent cell proliferation through evasion of cytotoxicity induced by apoptosis and autophagy in MM cells. HEG1-dependent/mediated miR-23b signaling may therefore be a potential target for MM diagnosis and therapy.
Free Research Field	病理診断
Academic Significance and Societal Importance of the Research Achievements	悪性中皮腫におけるHEG1の位置付けを明らかにすることで病理組織診断および予後との関連性が明らかになる。また、HEG1およびmiRNAとその標的候補分子による早期診断と予後予測、さらには分子標的治療に役立つ。